

## Nice & Green provides funding of 5.4 million euros to Marinomed Biotech AG as part of the plans to advance its scientific and clinical programs

Nyon, October 5, 2021 – Nice & Green, the Swiss investment firm, announces today the signing of a new investment agreement of up to 5.4 million euros with Marinomed Biotech AG (VSE:MARI), the Austrian biopharmaceutical company with globally marketed therapeutics in the field of respiratory and ophthalmic diseases. Marinomed plans to conduct scientific and clinical research for its two proprietary assets, the virus blocking Carragelose technology and the Marinosolv platform for the solubilization of pharmaceutical compounds.

The investment agreement between Nice & Green and Marinomed will be unfolded through a flexible Convertible Bonds program for an amount of up to EUR 300,000 per tranche over a contractual period of 23 months. The purpose of this transaction is to support the company's growth and enhance Marinomed's scientific and medical programs.

Pascal Schmidt, CFO of Marinomed, said: "We are excited about the potential of our technologies to improve treatments and prevent disease. This funding program provides us with high flexibility in advancing our ongoing and planned scientific and clinical programs and supports our corporate growth. Nice & Green have proven to be a long-term investor for several companies, and we warmly welcome them as our new investor and greatly appreciate their commitment and expertise."

Benoit Villers, Managing Partner at Nice & Green, added: "As an independent investment firm, we are devoted to helping innovative small and mid-cap companies grow by providing them with tailored financing programs. We strongly believe in Marinomed's equity story and are happy to invest in the further development of their novel therapeutics and technologies."

### About Marinomed Biotech AG

Marinomed Biotech AG (VSE:MARI) is an Austrian biopharmaceutical company. It specializes in the development of innovative products based on patent protected technology platforms in the field of respiratory and ophthalmic diseases. Marinomed has developed two platforms to date: the Marinosolv® technology platform and the Carragelose® platform. Find out more at [marinomed.com](https://www.marinomed.com).

### About Nice & Green

Nice & Green is a privately held Swiss investment firm providing innovative and tailor-made alternative financing solutions for small and mid-sized listed companies. Nice & Green helps ambitious companies secure funding needed for their growth and strives to establish long term financial partnerships with them. Find out more at [nicengreen.ch](https://www.nicengreen.ch).

### Contact Information

---

**Michèle Aouad**  
Head of Marketing & Communications

+41 22 361 36 97  
[maouad@nicengreen.ch](mailto:maouad@nicengreen.ch)